{"page_content": " 9 ALKERMES \u2022  CORPORATE RESPONSIBILITY REPORT \u2022 OUR RESPONSE TO COVID-19additional ~1,400 sites in 2021. As of the publication of this \nreport, patients can receive injections at more than 9,300 sites \nacross the United States.\nSupporting Ongoing Research  \nand Development\nFor our ongoing clinical trials, we have interacted closely \nwith clinical trial sites to develop new approaches to support \ncontinuity of care for participants in our studies and to identify \nadditional ways to streamline study visits and enhance data \ncollection to further reduce the burden on patients and the \nclinical teams. Supporting our Communities \nUnlike many other business challenges, the emergence \nof COVID-19 directly impacted our families, friends and \ncommunities, amplifying the importance of taking care of one \nanother and preserving our ability to meet the needs of people \nwho may benefit from our medicines. In 2021, we adapted \nour long-standing Alkermes in Action employee volunteer \nprogram to provide both virtual and in-person opportunities \nfor employees to give back to the communities where we are \nlocated.   \n", "metadata": {"source": "NASDAQ_ALKS_2022.pdf", "page": 8, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}